Human IGF2BP3 (Insulin Like Growth Factor 2 mRNA Binding Protein 3) CLIA Kit (HUES00315)

IGF2BP3 (also known as IMP3, KOC, or VICKZ3) is a KH-domain-containing oncofetal RNA-binding protein that preferentially recognizes N6-methyladenosine (m6A) modified transcripts and shields them from microRNA-mediated decay. Confirmed mRNA ligands include IGF2, MYC, and CD44, linking IGF2BP3 to proliferation, adhesion, invadopodia formation, and drug-resistance phenotypes across multiple tumor types.

For reliable quantification, collect serum or plasma into appropriate tubes, centrifuge at approximately 1000 x g for 15 minutes, and aliquot into single-use vials to limit freeze-thaw cycles; hemolyzed or lipemic specimens should be avoided because they elevate background chemiluminescence. The standard run is performed at room temperature and is typically completed within 3.5 hours, with intra-assay CV generally reported below 10% and inter-assay CV below 12% across the calibrated dynamic range. Researchers often pair circulating IGF2BP3 measurements with immunohistochemistry on formalin-fixed paraffin-embedded sections to correlate serum concentrations with tissue-level expression in tumor pathology studies. Assay Genie validation data support use of this CLIA kit for translational oncology workflows where chemiluminescent readout is preferred over colorimetric ELISA.